Sigma-1受体:抑郁症治疗的新靶点  

Sigma-1 receptor:a new therapeutic target for major depressive disorder

作　　者：陈红蕾 任鹏 李云峰 CHEN Honglei;REN Peng;LI Yunfeng(Graduate Collaborative Training Base of Academy of Military Medical Sciences,Academy of Military Sciences,Hengyang Medical School,University of South China,Hengyang,Hunan 421001,China;Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100850,China)

机构地区：[1]南华大学衡阳医学院军事科学院军事医学研究院研究生协作培养基地,湖南衡阳421001 [2]军事科学院军事医学研究院,北京100850

出　　处：《军事医学》2024年第7期554-560,共7页Military Medical Sciences

基　　金：国家自然科学基金项目(82304462,82204360,82204358)。

摘　　要：抑郁症是一种以持久心境低落、兴趣丧失和认知功能受损为特点的精神性疾病。目前临床上使用的抗抑郁药常伴随着诸多不良反应,如起效缓慢、损伤认知、致性功能障碍等。因此,探索具有快速起效、增强认知和低不良反应特性的新一代抗抑郁药物靶点和治疗策略,已成为该领域的热点研究方向。研究表明,Sigma⁃1受体通过调节炎症反应、兴奋/抑制平衡、内质网稳态等在抗抑郁过程中发挥着重要作用,且Sigma⁃1受体激动剂可能具有快速起效、增强认知、低不良反应等优点,为新型抗抑郁药的研发展示了良好前景。该文综述了Sigma⁃1受体在抑郁症调控机制和治疗研究领域的进展,旨在为抑郁症的治疗及新型抗抑郁药物的研发提供新思路。Major depressive disorder(MDD)is a mental disease characterized by persistent depression,lack of interest and impaired cognitive function.Antidepressants currently availablein clinic are effective but accompanied by many adverse reactions,such as slow onset,cognitive impairment,sexual dysfunction.Therefore,novel antidepressant targets and therapeutic strategies with rapid onset of action,cognitive enhancement and low adverse effects have increasingly become a promising sphere of research.Studies have suggested that Sigma⁃1 receptor plays an important role in combating depression by regulating inflammatory response,excitation/inhibition balance and endoplasmic reticulum homeostasis.Moreover,Sigma⁃1 receptor agonists may have the advantages of rapid onset,enhanced cognition and low adverse reactions,which show good prospects for the development of new antidepressants.This article reviews the research progress related to Sigma1 receptors in the regulatory mechanism and treatments for depression in the hopes of providing new insights into new antidepressants.

关 键 词：Sigma⁃1受体 抑郁症 靶点 机制 临床研究 

分 类 号：R749.4[医药卫生—神经病学与精神病学]